menu search

Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA

Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA
Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended to slow disease progression in subjects with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) There are no approved oral or non-invasive treatments for GA Enrollment of approximately 430 GA subjects across multiple centers globally SAN DIEGO, July […] The post Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for... Read More
Posted: Jul 27 2023, 21:00
Author Name: forextv
Views: 080848

Search within

Pages Search Results: